341 related articles for article (PubMed ID: 23143305)
1. Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.
Çuburu N; Graham BS; Buck CB; Kines RC; Pang YY; Day PM; Lowy DR; Schiller JT
J Clin Invest; 2012 Dec; 122(12):4606-20. PubMed ID: 23143305
[TBL] [Abstract][Full Text] [Related]
2. Topical herpes simplex virus 2 (HSV-2) vaccination with human papillomavirus vectors expressing gB/gD ectodomains induces genital-tissue-resident memory CD8+ T cells and reduces genital disease and viral shedding after HSV-2 challenge.
Çuburu N; Wang K; Goodman KN; Pang YY; Thompson CD; Lowy DR; Cohen JI; Schiller JT
J Virol; 2015 Jan; 89(1):83-96. PubMed ID: 25320297
[TBL] [Abstract][Full Text] [Related]
3. A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8
Çuburu N; Kim R; Guittard GC; Thompson CD; Day PM; Hamm DE; Pang YS; Graham BS; Lowy DR; Schiller JT
J Immunol; 2019 Feb; 202(4):1250-1264. PubMed ID: 30635393
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
5. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
6. Targeting the genital tract mucosa with a lipopeptide/recombinant adenovirus prime/boost vaccine induces potent and long-lasting CD8+ T cell immunity against herpes: importance of MyD88.
Zhang X; Dervillez X; Chentoufi AA; Badakhshan T; Bettahi I; Benmohamed L
J Immunol; 2012 Nov; 189(9):4496-509. PubMed ID: 23018456
[TBL] [Abstract][Full Text] [Related]
7. Induction of vaginal-resident HIV-specific CD8 T cells with mucosal prime-boost immunization.
Tan HX; Wheatley AK; Esterbauer R; Jegaskanda S; Glass JJ; Masopust D; De Rose R; Kent SJ
Mucosal Immunol; 2018 May; 11(3):994-1007. PubMed ID: 29067995
[TBL] [Abstract][Full Text] [Related]
8. Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination.
Graham BS; Kines RC; Corbett KS; Nicewonger J; Johnson TR; Chen M; LaVigne D; Roberts JN; Cuburu N; Schiller JT; Buck CB
Mucosal Immunol; 2010 Sep; 3(5):475-86. PubMed ID: 20555315
[TBL] [Abstract][Full Text] [Related]
9. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule.
Gherardi MM; Pérez-Jiménez E; Nájera JL; Esteban M
J Immunol; 2004 May; 172(10):6209-20. PubMed ID: 15128809
[TBL] [Abstract][Full Text] [Related]
10. Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
Green CA; Scarselli E; Sande CJ; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Del Sorbo M; Angus B; Siani L; Di Marco S; Traboni C; Folgori A; Colloca S; Capone S; Vitelli A; Cortese R; Klenerman P; Nicosia A; Pollard AJ
Sci Transl Med; 2015 Aug; 7(300):300ra126. PubMed ID: 26268313
[TBL] [Abstract][Full Text] [Related]
11. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
12. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
13. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
[TBL] [Abstract][Full Text] [Related]
14. Retinoic acid as a vaccine adjuvant enhances CD8+ T cell response and mucosal protection from viral challenge.
Tan X; Sande JL; Pufnock JS; Blattman JN; Greenberg PD
J Virol; 2011 Aug; 85(16):8316-27. PubMed ID: 21653670
[TBL] [Abstract][Full Text] [Related]
15. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope.
Harrington LE; Most Rv Rv; Whitton JL; Ahmed R
J Virol; 2002 Apr; 76(7):3329-37. PubMed ID: 11884558
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles.
Kines RC; Zarnitsyn V; Johnson TR; Pang YY; Corbett KS; Nicewonger JD; Gangopadhyay A; Chen M; Liu J; Prausnitz MR; Schiller JT; Graham BS
PLoS One; 2015; 10(3):e0120797. PubMed ID: 25785935
[TBL] [Abstract][Full Text] [Related]
17. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
18. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer.
Echchannaoui H; Bianchi M; Baud D; Bobst M; Stehle JC; Nardelli-Haefliger D
Infect Immun; 2008 May; 76(5):1940-51. PubMed ID: 18332214
[TBL] [Abstract][Full Text] [Related]
19. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
20. Role of novel type I interferon epsilon in viral infection and mucosal immunity.
Xi Y; Day SL; Jackson RJ; Ranasinghe C
Mucosal Immunol; 2012 Nov; 5(6):610-22. PubMed ID: 22617838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
